HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer ; volume:14 ; number:1 ; day:27 ; month:5 ; year:2024 ; pages:1-14 ; date:12.2024
Scientific reports ; 14, Heft 1 (27.5.2024), 1-14, 12.2024
- Urheber
-
Kapil, Ansh
Spitzmüller, Andreas
Brieu, Nicolas
Haneder, Susanne
Shumilov, Anatoliy
Meier, Armin
Cecchi, Fabiola
Barkell, Alice
Harder, Nathalie
Mittermaier, Katrin
Hidalgo-Sastre, Ana
Alleze, Regina
Schick, Markus
Schmidt, Günter
Sade, Hadassah
Tsuchihashi, Zenta
Suto, Fumitaka
Gustavson, Mark
Barrett, J. Carl
Carroll, Danielle
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-61957-9
- URN
-
urn:nbn:de:101:1-2408060902350.387872700786
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kapil, Ansh
- Spitzmüller, Andreas
- Brieu, Nicolas
- Haneder, Susanne
- Shumilov, Anatoliy
- Meier, Armin
- Cecchi, Fabiola
- Barkell, Alice
- Harder, Nathalie
- Mittermaier, Katrin
- Hidalgo-Sastre, Ana
- Alleze, Regina
- Schick, Markus
- Schmidt, Günter
- Sade, Hadassah
- Tsuchihashi, Zenta
- Suto, Fumitaka
- Gustavson, Mark
- Barrett, J. Carl
- Carroll, Danielle
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Enhertu (Trastuzumab-Deruxtecan) : Therapieerfahrungen bei Patient*innen mit HER2-positivem und HER2-low fortgeschrittenem Mammakarzinom
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE